Close Sidebar
Nordic Life Science
Now Reading
Ultimovacs implements operational adjustments, including reducing its workforce
Search for content, post, videos
Search for content, post, videos
Advertisement

Ultimovacs implements operational adjustments, including reducing its workforce

April 17, 2024
378 Views
Carlos de Sousa
Ultimovacs has announced a plan to optimize its business operations to support the continuous advancement of UV1 and long-term business growth. “We remain dedicated to our investigation of the potential impact of UV1 vaccine across several cancer indications and immunotherapy combinations, and
Already a subscriber Login

You have read all your free articles, to continue reading subscribe to read the rest of this content.

Related Posts

February 20, 2023

Aqilion has announced an exclusive license and strategic research collaboration with Merck to discover, develop and commercialize small molecule inhibitors of the transforming growth factor-β-activated kinase 1 (TAK1) protein. “We are delighted and proud to announce this collaboration with MerAlready a subscriber Login You have read all your free articles,…

Martin Åmark
December 14, 2021

Xbrane Biopharma has announced the initiation of developing two new biosimilar candidates referencing Keytruda and Darzalex respectively. Together with the continued development of Xdivane, a biosimilar candidate referencing Opdivo, this forms an oncology biosimilar portfolio addressing 23 billioAlready a subscriber Login You have read all your free articles, to continue…

Göran Forsberg Photo Håkan Sandbring
October 31, 2023

The board of directors of Cantargia has resolved to carry out a directed new issue of 16,698,789 shares at a subscription price of SEK 3.55 per share. The Directed Share Issue will provide Cantargia with approximately SEK 59.3 million before deduction of transaction costs. Investors in the DirAlready a subscriber…

personalized medicine
February 27, 2024

The European Medicines Agency (EMA) has granted Priority Medicines (PRIME) designation to Aurealis Therapeutics’ lead product candidate AUP-16 for the treatment of non-healing Diabetic Foot Ulcers (nhDFU). “With the PRIME status and support by EMA, we aim to expedite the further development oAlready a subscriber Login You have read all…